Fourteen piglets (<24 hrs old, mean wt 1.5 kg) had aortic catheters placed one day prior to study. Mean Aortic pressure (MAD) was measured continuously during the study. Ionized calcium levels were drawn on all animals and then a bolus infusion of 300 ug/kg of verapamil was administered. Five control animals received no further therapy. Nine animals were given 1 m g glucagon boluses one minute following verapamil.
Ionized calcium was 4.9 mg?b or greater prior to the study (nl = 4.1-5.1) in all animals. Verapamil induced hypotension in both groups. The average M A P fell from 66 to 56 m m H g (17%) in the treatment group and from 70 to 61 (13%) the control. Heart rate (H9) also slowed both in the treatment group from a mean of 220 to 200 and in the controls from 200 to 180. Glucagon failed to reverse the hypotension in the nine treated animals ( V A P 54 Treated, 63 Control). HR did not return to baseline (HR 190 Treated, 180 Control We have previously demonstrated an apparent decrease in renal tubular secretion and an increase in plasma half-life for furosemide (F) in VLBW infants. To pharmacokinetically characterize maturation of furosemide's tubular secretory pathway(s) and investigate whether pharmacodynamic effects such as sodium excretion undergo similar developmental changes, 3 and 18 day old piglets were administered a) an i.v. bolus dose or b) a primed continuous i.v. infusion of F, with quantitative fluid replacement. Plasma and urinary sodium and F levels, urine output and GFR were measured. Intrinsic secretory clearance of unbound F was calculated as were dose-response curves expressed as sodium excretion rate vs. log furosemide excretion rate. Mean intrinsic secretory clearance was significantly lower in the younger age group (51.7 vs. 104 ml/min/kg, p<0.01). While basal responses and slopes of the dose-response curves did not differ significantly, maximal response was increased in the older piglets (0.63 vs. 1.18 m mole Nalmin, ~(0.05). The F excretion rate required to stimulate a half-maximal response. however, was lower in the younger animals (0.06 vs. 0.15 pmoles Flmin, ~(0.01) and indicated an increased sensitivity to the drug. Thus the net response to F is a balance of maturational factors which influence both drug delivery and tubular responsiveness. Purosemide (F) pharmacodynamics in VLBW infants have not been described following initial and subsequent doses during chronic adminstration. F acts from the luminal side of the loop of Henle and there is a log dose-response relationship between diuretic responses (Na excretion rate, urine output) and F urinary excretion rate. Serial urine collections were performed on 8 VLBW infants begun on F for treatment of BPD. Urine volume and F and sodium concentrations were measured. A linear relationship between diuretic response and F excretion rate was noted in all patients. Natriueetic response (mEq/hr) to initial doses of F decreased significantly with increasing gestational age (p<.02). The F excretion rate required to produce a standard diuretic response was significantly greater (~=.05) during chronic administration than following the initial dose. No consistent pattern of maturation of diuretic response was noted during subsequent chronic administration. We conclude that apparent sensitivity to F decreases with increasing gestational age at the start of therapy and with subsequent chronic doses. These changes may reflect the ability of the renal tubule to compensate for diuretic induced sodium and water loss. Results of previous studies of furosemide pharmacodynamics in VLBW infants following single initial doses can not be extrapolated to chronic administration. In order to investigate an apparent increase in the number of NICU newborns (NBs) with unexplained DHB, a retrospective analysis of all NBs admitted to the NICU over an 18 month period was conducted. The study revealed 11 newborns with undiagnosed DHB defined as direct bilirubin) 2 mg/dl or) 10% of the total bilirubin level. Four of the 11 NBs had identifiable factors which are known to cause DHB. Two of the 4 NBs had severe perinatal asphyxia with elevated liver enzymes and 2 NBs had prolonged hyperalimentation due to gastrointestinal adnormalities.
All of the remaining 7 NBs (Group 1) did not have a diagnosable nor identifiable cause, but all had received CH 30-40 mglkg q 4-6 h for sedation while on the ventilator. In these NBs, the DHB began to decrease within 2 days of the last CH dose. We next reviewed all charts of NBs who had received more than one dose of CH for sedation and did not have DHB (Group 2). The 
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